Join the #FierceMadness!
Pick your favorite drug names in this year's tournament challenge. Read more and vote here!
Mylan is suffering in the U.S. thanks to stepped-up pricing pressure. But it’s hoping a new biosimilar can eventually help its stateside sales.
Bayer's Monsanto deal hasn't even closed yet, and healthcare sales are already showing cause for concern.
Clinical care experts and patient advocacy organizations call attention to why better patient understanding shapes the best integrated approach to orphan drug…
Sources have told Reuters that Novartis is preparing to auction off its U.S. generics pills business.
Teva may be decimating its employee ranks and struggling under a mountain of debt, but Warren Buffett apparently likes what he sees.
One analyst takeaway from Shire’s 2018 outlook: Consensus earnings estimates probably need to come down.
Teva just went through a horrible year, today reporting a $17.5 billion operating loss in 2017, but execs said things will get worse before they get better.…
AstraZeneca said its potential blockbuster hyperkalemia drug ZS-9 is back on track after the FDA rejected it in 2016 due to manufacturing issues at its Texas…
Sanofi Genzyme, which specializes in rare diseases, said it will let go of 130 workers at its Allston Landing biomanufacturing facility in Boston.
The decision by two leading pharmacy benefit managers to exclude Sanofi's big-sellers in diabetes took a toll in 2017.
GlaxoSmithKline today said that it has been asked for new info on its 2013 China bribery scandal for the U.K.’s Serious Fraud Office.